AmplideX® PCR/CE FMR1 Reagents
AmplideX PCR/CE FMR1 Reagents* are market-leading research tools for the detection of CGG repeats in the fragile X mental retardation (FMR1) gene. These reagents provide a PCR-only approach based on Triplet Repeat Primed PCR (TP-PCR) design to reliably amplify and detect all alleles including Full Mutations.
Features & Benefits
AmplideX PCR/CE FMR1 Reagents* have created an easy-to-use, accessible, high performance method for laboratories to reliably analyze CGG repeats and detect interrupting AGG sequences in the FMR1 gene.
Reduced ComplexityEase-of-analysis of the FMR1 gene has been simplified through:
- Implementation of proprietary PCR solution for amplifying GC-rich regions
- Automation of result calling using AmplideX PCR/CE FMR1 Reporter*
Optimized WorkflowValuable operator hands-on time has been significantly reduced through:
- Direct injection of PCR products (no PCR clean up) in to Capillary Electrophoresis platforms
- Decreased need for Southern blot analysis (up to 50 fold)
- End-to-end solution for FMR1 analysis including all necessary reagents and software
Quality PerformancePerforming FMR1 Analysis with Greater Sensitivity and Accuracy:
- Detection of all allele expansions, including low abundance full mutation size mosaics with up to at least 1300 CGG repeats
- Up to 875 fold more sensitive than Southern blot1
- Resolution of female homozygous and heterozygous samples and indication of interrupting AGG sequences
- Proven performance as indicated by more than 30 peer reviewed publications
*For Research Use Only. Not for use in diagnostic procedures.

Product Description
Analytical Characteristics of AmplideX PCR/CE FMR1 Reagents*:
- Detects all alleles including low abundance full mutations (Figure 1)
- Accurately sizes any repeat up to 200 CGG repeats (Figure 2)
- Resolves female zygosity (Figure 3)
- Detects presence of AGG interruptions (Figure 4)
Figure 1: Amplification of Asuragen’s Methylation and Sensitivity Control which has a 5% full mutation in a background of 95% Normal

Figure 2. Female premutation sample with accurate sizing of Normal (30 CGG) and Pre mutation allele (56 CGG)

Figure 3: The difference in the “stutter” peak patterns of homozygous and heterozygous female provides a clear resolution of zygosity

Figure 4. Female Full Mutation sample with AGG interruptions as indicated by sudden decrease in peak heights of the “stutter” peak profile

Ordering
| Product Name | Number of Reactions | Catalog Number |
|---|---|---|
| AmplideX PCR/CE FMR1 Control | 24 UL | 49513 |
| AmplideX mPCR FMR1 Control | 24 UL | 49514 |
| AmplideX PCR/CE FMR1 Reagents | 100 | 49402 |
| AmplideX mPCR FMR1 Kit | 24 | 49442 |
| AmplideX PCR/CE FMR1 Reporter | N/A | 49576 |
T 1-877-777-1874; 512-681-5200 F 512-681-5202 E orders@asuragen.com
References
- Referenced in over 30 peer reviewed publications and used in over 200 laboratories, the AmplideX® PCR/CE FMR1 Reagents* are globally recognized as best-in-class for assessment of CGG repeats in the FMR1 gene.
- Key resources
- Videos
AmplideX® PCR/CE FMR1 Kit
AmplideX PCR/CE FMR1 Kit is an in vitro diagnostic (IVD) device for use in clinical laboratories for detection of the CGG repeats in the fragile X mental retardation (FMR1) gene. The device is intended to aid in the diagnosis of fragile X syndrome and fragile X associated disorders, e.g. tremor and ataxia syndrome (FX-TAS) and primary ovarian insufficiency (FXPOI), through determination of CGG repeat length up to 200 CGG and detection of alleles greater than 200 CGG. The kit provides a PCR-only approach based on Triplet Repeat Primed PCR (TP-PCR) design to reliably amplify and detect all alleles including Full Mutations.
Features & Benefits
AmplideX PCR/CE FMR1 Kit has created an easy-to-use, accessible, high performance method for laboratories to reliably analyze CGG repeats and detect interrupting AGG sequences in the FMR1 gene.
Reduced ComplexityEase-of-analysis of the FMR1 gene has been simplified through:
- Implementation of proprietary PCR solution for amplifying GC-rich regions
- Automation of result calling using AmplideX PCR/CE FMR1 Reporter
Optimized WorkflowValuable operator hands-on time has been significantly reduced through:
- Direct injection of PCR products (no PCR clean up) in to Capillary Electrophoresis platforms
- Decreased need for Southern blot analysis (up to 50 fold)
- End-to-end solution for FMR1 analysis including all necessary reagents and software
Quality PerformancePerforming FMR1 Analysis with Greater Sensitivity and Accuracy:
- Detection of all allele expansions, including low abundance full mutation size mosaics with up to at least 1300 CGG repeats
- Up to 875 fold more sensitive than Southern blot1
- Resolution of female homozygous and heterozygous samples and indication of interrupting AGG sequences
- Proven performance as indicated by more than 30 peer reviewed publications
Product Description
Analytical Characteristics of AmplideX PCR/CE FMR1 Kit:
- Proven clinical accuracy compared to Southern Blot (Table 1)
- Detects all alleles including low abundance full mutations (Figure 1)
- Accurately sizes all alleles up to 200 CGG repeats (Figure 2)
- Resolves female zygosity (Figure 3)
- Detects presence of AGG interruptions (Figure 4)
Table 1: Diagnostic Sensitivity of 100%; Diagnostic Specificity of 98.4% and Overall Accuracy of 99%
*These 2 samples presented premutation alleles by both methods and low intensity full mutation alleles detected only by the AmplideX PCR/CE FMR1 Kit
Figure 1: Amplification of Asuragen’s Methylation and Sensitivity Control which has a 5% full mutation in a background of 95% Normal

Figure 2. Female Pre-mutation sample with accurate sizing of Normal (30 CGG) and Pre-mutation allele (56 CGG)

Figure 3: The difference in the “stutter” peak patterns of homozygous and heterozygous female provides a clear resolution of zygosity

Figure 4. Female Full Mutation sample with AGG interruptions as indicated by sudden decrease in peak heights of the “stutter” peak profile

Ordering
| Product Name | Number of Reactions | Catalog Number |
|---|---|---|
| AmplideX PCR/CE FMR1 Control* | 24 UL | 49513 |
| AmplideX mPCR FMR1 Control* | 24 UL | 49514 |
| AmplideX PCR/CE FMR1 Reagents* | 100 | 49402 |
| AmplideX PCR/CE FMR1 Kit | 100 | 76008 |
| AmplideX mPCR FMR1 Kit* | 24 | 49442 |
| AmplideX PCR/CE FMR1 Reporter* | N/A | 49576 |
T 1-877-777-1874; 512-681-5200 F 1-512-681-5202 E orders@asuragen.com
References
- Referenced in over 30 peer reviewed publications and used in over 200 laboratories, the AmplideX® PCR/CE FMR1 Reagents* are globally recognized as best-in-class for assessment of CGG repeats in the FMR1 gene.
- Key resources
- Videos
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
在这种测定方法中有3种必要的试剂:①固相的抗原或抗体(免疫吸附剂) ②酶标记的抗原或抗体(标记物)③酶作用的底物(显色剂)
测量时,抗原(抗体)先结合在固相载体上,但仍保留其免疫活性,然后加一种抗体(抗原)与酶结合成的偶联物(标记物),此偶联物仍保留其原免疫活性与酶活性,当偶联物与固相载体上的抗原(抗体)反应结合后,再加上酶的相应底物,即起催化水解或氧化还原反应而呈颜色。
其所生成的颜色深浅与欲测的抗原(抗体)含量成正比。 这种有色产物可用肉眼、光学显微镜、电子显微镜观察,也可以用分光光度计(酶标仪)加以测定。其方法简单,方便迅速,特异性强。向左转|向右转
目前,我用该蛋白的鼠源性单抗来包被ELISA板子,5%BSA37度封闭二小时后,洗涤四次后将板子分三个组加入抗原:其中一个组中加入的是我重组的蛋白,另一个组为用其它方法证实含该蛋白的人体内血清,最后一个组加入PBS。37度一小时后洗涤四次后每孔加入我制备的兔源性多抗。37度一小时洗涤六次后我再加入酶标记的抗兔的抗体37度40分钟后洗涤六次后TMB显色。
问题就在我显色后所有的孔都是阳性,其中以抗原为我的重组蛋白组与PBS组OD值最高,两组都可以达到1.8以上,而加入的抗原为人体血清组低,为0.6-1.0不等。
后面我优化条件,封闭液用过5%的脱脂奶粉,2%的BSA,包被的单抗浓度摸了梯度,加入的多抗也摸了梯度,酶标的抗体也摸了梯度。结果都没有改变,连趋势每次都是一样以重组蛋白组与PBS组OD最高。
今天我还试着把抗原换成其它蛋白也做出了强阳性?
请教各位高手,我的ELISA该如何往下面做了啊,是不是我的抗体本身有问题呢?
对了,我包被用的单抗是用GE公司的预装柱纯化的,很纯,在考染中是看不到一条杂带的。
1. 直接法测定抗原 2.间接法测定抗体 3.双抗体夹心法测定抗原4. 竞争法测定抗原 厚百生物专业提供各类生化实验试剂、仪器、耗材,提供技术服务,满足您的实验室常规采购需求。厚百,让您更省心!
(1) 包被:用0.05M PH9.牰碳酸盐包被缓冲液将抗体稀释至蛋白质含量为1~10μg/ml。在每个聚苯乙烯板的反应孔中加0.1ml,4℃过夜。次日,弃去孔内溶液,用洗涤缓冲液洗3次,每次3分钟。(简称洗涤,下同)。
(2) 加样:加一定稀释的待检样品0.1ml于上述已包被之反应孔中,置37℃孵育1小时。然后洗涤。(同时做空白孔,阴性对照孔及阳性对照孔)。
(3) 加酶标抗体:于各反应孔中,加入新鲜稀释的酶标抗体(经滴定后的稀释度)0.1ml。37℃孵育0.5~1小时,洗涤。
(4) 加底物液显色:于各反应孔中加入临时配制的TMB底物溶液0.1ml,37℃10~30分钟。
(5) 终止反应:于各反应孔中加入2M硫酸0.05ml。
(6) 结果判定:可于白色背景上,直接用肉眼观察结果:反应孔内颜色越深,阳性程度越强,阴性反应为无色或极浅,依据所呈颜色的深浅,以“+”、“-”号表示。也可测O·D值:在ELISA检测仪上,于450nm(若以ABTS显色,则410nm)处,以空白对照孔调零后测各孔O·D值,若大于规定的阴性对照OD值的2.1倍,即为阳性。
间接法:
用包被缓冲液将已知抗原稀释至1~10μg/ml,每孔加0.1ml,4℃过夜。次日洗涤3次。加一定稀释的待检样品(未知抗体)0.1ml于上述已包被之反应孔中,置37℃孵育1小时,洗涤。(同时做空白、阴性及阳性孔对照)于反应孔中,加入新鲜稀释的酶标第二抗体(抗抗体)0.1ml,37℃孵育30-60分钟,洗涤,最后一遍用DDW洗涤。其余步骤同“双抗体夹心法”的4、5、6。
1) 将特异性抗体与固相载体联结,形成固相抗体.洗涤除去未结合的抗体及杂质.
2) 加受检标本,保温反应.标本中的抗原与固相抗体结合,形成固相抗原抗体复合物.洗涤除去其他未结合物质.
3) 加酶标抗体,保温反应.固相
免疫
复合物上的抗原与酶标抗体结合.彻底洗涤未结合的酶标抗体.此时固相载体上带有的酶量与标本中受检抗原的量相关.
4) 加底物显色.固相上的酶催化底物成为有色产物.通过比色,测知标本中抗原的量.在临床检验中,此法适用于检验各种蛋白质等大分子抗原,例如HBsAg,HBeAg,AFP,hCG等.只要获得针对受检抗原的异性抗体,就可用于包被固相载体和制备酶结合物而建立此法.如抗体的来源为抗血清,包被和酶标用的抗体最好分别取自不同种属的动物.如应用单克隆抗体,一般选择两个针对抗原上不同决定簇的单抗,分别用于包被固相载体和制备酶结合物.这种双位点夹心法具有很高的特异性,而且可以将受检标本和酶标抗体一起保温反应,作一步检测.
在一步法测定中,当标本中受检抗原的含量很高时,过量抗原分别和固相抗体及酶标抗体结合,而不再形成"夹心复合物".类同于沉淀反应中抗原过剩的后带现象,此时反应后显色的吸光值(位于抗原过剩带上)与标准曲线(位于抗体过剩带上)某一抗原浓度的吸光值相同(参见1.3.2,图1-4),如按常法测读,所得结果将低于实际的含量,这种现象被称为钩状效应(hook effect),因为标准曲线到达高峰后呈钩状弯落.钩状效应严重时,反应甚至可不显色而出现假阴性结果.因此在使用一步法试剂测定标本中含量可异常增高的物质(例如血清中HBsAg,AFP和尿液hCG等)时,应注意可测范围的最高值.用高亲和力的单克隆抗体制备此类试剂可削弱钩状效应.
假使在被测分子的不同位点上含有多个相同的决定簇,例如HBsAg的a决定簇,也可用针对此决定的同一单抗分别包被固相和制备酶结合物.但在HBsAg的检测中应注意亚型问题,HBsAg有adr,adw,ayr,ayw4个亚型,虽然每种亚型均有相同的a决定簇的反应性,这也是用单抗作夹心法应注意的问题.
双抗体夹心法测抗原的另一注意点是类风湿因子(RF)的干扰.RF是一种自身抗体,多为IgM型,能和多种动物IgG的Fc段结合.用作双抗体夹心法检测的血清标本中如含有RF,它可充当抗原成份,同时与固相抗体和酶标抗体结合,表现出假阳性反应.采用F(ab')或Fab片段作酶结合物的试剂,由于去除了Fc段,从而消除RF的干扰.双抗体夹心法ELISA试剂是否受RF的影响,已被列为这类试剂的一项考核指标(参见6.2).
双抗体夹心法适用于测定二价或二价以上的大分子抗原,但不适用于测定半抗原及小分子单价抗原,因其不能形成两位点夹心.
2.2 双抗原夹心法测抗体
反应模式与双抗体夹心法类似.用特异性抗原进行包被和制备酶结合物,以检测相应的抗体.与间接法测抗体的不同之处为以酶标抗原代替酶标抗抗体.此法中受检标本不需稀释,可直接用于测定,因此其敏感度相对高于间接法.乙肝标志物中抗HBs的检测常采用本法.本法关键在于酶标抗原的制备,应根据抗原结构的不同,寻找合适的标记方法.
竞争法测抗体
当抗原材料中的干扰物质不易除去,或不易得到足够的纯化抗原时,可用此法检测特异性抗体.其原理为标本中的抗体和一定量的酶标抗体竞争与固相抗原结合.标本中抗体量越多,结合在固相上的酶标抗体愈少,因此阳性反应呈色浅于阴性反应.如抗原为高纯度的,可直接包被固相.如抗原中会有干扰物质,直接包被不易成功,可采用捕获包被法,即先包被与固相抗原相应的抗体,然后加入抗原,形成固相抗原.洗涤除去抗原中的杂质,然后再加标本和酶标抗体进行竞争结合反应.竞争法测抗体有多种模式,可将标本和酶标抗体与固相抗原竞争结合,抗HBc ELISA一般采用此法.另一种模式为将标本与抗原一起加入到固相抗体中进行竞争结合,洗涤后再加入酶标抗体,与结合在固相上的抗原反应.抗HBe的检测一般采用此法.
2.5 竞争法测抗原
小分子抗原或半抗原因缺乏可作夹心法的两个以上的位点,因此不能用双抗体夹心法进行测定,可以采用竞争法模式.其原理是标本中的抗原和一定量的酶标抗原竞争与固相抗体结合.标本中抗原量含量愈多,结合在固相上的酶标抗原愈少,最后的显色也愈浅.小分子激素,药物等ELISA测定多用此法.
如果用双抗体夹心法,第二个抗体可以用多抗,这样保证你的抗原会被结合,多抗可以直接带HRP标记或者可以用HRP标记二抗去和多抗结合。

